Lin BioScience

Blindness & Cancer

2021

First-in-Class Treatment for Unmet Medical Need

Lin Bioscience is a clinical stage drug development company focused on sourcing/advancing first-in-class therapeutic candidates in areas with significant unmet need, and then out-license these assets for partnership. The Company's pipeline consists 2 technology platforms (RBP4 platform & CDC7 platform) and 4 distinct small molecule drug candidates. LBS-008, targeted to treat Stargardt disease and dry age-related macular degeneration ("Dry AMD"), and LBS-009, targeted to treat NASH, derived from the RBP4 platform technology are developed by Belite Bio, a subsidiary company of Lin BioScience. LBS-007, developed from the CDC7 platform technology and targeted to treat various cancers, and LBS-002, targeted to treat glioblastomas and metastatic brain tumors, are developed by Lin BioScience.

LBS-007 is a non-ATP competitive CDC7 inhibitor for the treatment of a broad array of cancers, especially for refractory/relapsed and late-stage cancers such as AML, ALL, ovarian cancer, pancreatic cancer, etc., which is expected to enter phase 1 in 2021.

LBS-008 is the only drug treating dry AMD selected by the NIH Blueprint Program ("BPN"), whose mission is to discover and develop therapies treating untreatable neurological disorders which cause huge impact to the US society. LBS-008's mechanism of action has been recognized and recommended in a systematic review published by the UK National Institute for Health Research ("NIHR") in 2018. BPN has provided $10mn funding on LBS-008. LBS-008 has initiated its phase 3 for Stargardt disease and expects to initiate its phase 3 for Dry AMD in 2022.

Johnson & Johnson

COLUMBIA UNIVERSITY

NIH National Institutes of Health

NIH Blueprint Neurotherapeutics Network

NHS National Institute for Health Research

Pipeline


Discovery
Pre-Clinical
Phase 1
Phase 2
Phase 3
MARKET
Developed by Belite Bio™
RBP4 Platform
LBS 008
Dry AMD
Stargardt Disease (juvenile macular degeneration)
Sponsored by NIH BPN
Obtained FDA RPD, FDA ODD, & EMA ODD
LBS 009
Non Alcoholic Fatty Liver Disease (NASH) / Type 2 Diabetes
Developed by Lin BioScience
Oncology Programs
LBS 007
Acute Leukemia (FDA ODD)
Multiple Solid Tumors
Sponsored by Taiwan Industrial Development Bureau's Innovation Platform Program
LBS 002
Glioblastoma / Brain Metastasis

Management Team

Tom Lin, MMED, PhD, MBA (CEO)

- **10 years of executive management role in biotech, incl. 2 IPO**
- **Multidisciplinary Specialization Clinical Training & Research in Neuroscience, Cardiovascular & Renal Medicine, Oncology, Immunology & Immunotherapy**
- **Over 10 new drug developments in multiple therapeutic areas, including Ophthalmology, CNS, Cardiovascular, Oncology, Immuno-Oncology, Immunotherapies, Immunosuppressants**
- **Drug development experience from drug discovery to Phase 3**

- **PhD in Medicine - University of Sydney**; Specialization: Neurology & Immunology
  - Treatment Strategies for Autoimmune Neuropathies
- **Specialist Certificate in Clinical Neuroscience - University of Melbourne**; Specialization: Neurology
  - Neurological Disorders, Neuroimaging & Diagnostics
  - Clinical Research & Design
- **Master of Medicine - University of Sydney**; Specialization: Multidisciplinary Medicine and Surgery
  - Medicine: Cardiovascular & Renal Medicine, Neonatal Medicine
  - Surgery: Vascular & Endovascular Surgery, Transplant Surgery
- **Cancer Therapeutics & Research Certificate - Harvard Medical School**
- **Master of Business Administration - Columbia University, London Business School, HK University**
- **Extensive Drug development from preclinical to global phase 3 trials**
  - Phase 1 – RBP4 Inhibitor for the Treatment of Atrophic Macular Degeneration & Stargardt Disease
  - Phase 2 – Oubain Antagonist in the Treatment of Essential Hypertension
  - Phase 2 – SERCA2a Inhibitor in the Treatment of Acute Heart Failure
  - Phase 2 – Pan-HER Inhibitor in the Treatment of HER2+ Breast Cancer and Gastric Cancer
  - Phase 3 – Anti-Glycan Active Immunotherapy in the Treatment of Metastatic Breast Cancer
  - Phase 3 – Anti-α4 integrin Antibody in the Treatment of Resistant-Refractory Multiple Sclerosis
  - Phase 2 – mTOR Immunosuppressant in the Treatment of Autoimmune Peripheral Neuropathies
  - Co-invented and applied 64 patents

Management Team

Irene Wang, PhD, MBA (CSO)

- PhD in Biochemical Sciences, National Taiwan University, Trained at Scripps Research (TSRI), MBA from UCSD
- Co-invented and applied 125 patents and published 6 papers
- Extensive Drug development from preclinical to global phase 3 trials

Hao-Yuan Chuang, CFA, MBA, FRM (CFO)

- MBA from Columbia University
- Served as Executive/Director positions, led transactions: Suning – US$320M acquisition of Inter-Milan; Wanda – US$10B property acquisition, bond issue and IPO; CITIC Securities International – Finance Advisor to Agricultural Bank of China's US$22B IPO

Yvonne Chen (COO)

- Certified pharmacist & master in Science (Medicinal Chemistry) from National Taiwan University
- Vast experience in clinical trial management and regulatory submissions with over 50 studies in various indications
- Served as Global Project Lead and Manager in Pfizer Taiwan

Ophthalmology Clinical Advisory Board

Global leading experts on dry age-related macular degeneration and Stargardt disease

- **Dr. Frank Holz:** Chairman of Ophthalmology, University of Bonn

- **Dr. Robyn Guymer:** Professor of Ophthalmology, University of Melbourne & Deputy Director of the Centre for Eye Research Australia

- **Dr. Quan Nguyen:** Professor of Ophthalmology, Stanford University

- **Dr. Janet Sunness:** Medical Director of Hoover Eye Center, Greater Baltimore Medical Center

- **Dr. Hendrik P.N. Scholl:** Co-Director of the Institute of Molecular and Clinical Ophthalmology, Basel & Professor and Chairman of the Department of Ophthalmology, University of Basel, and Adjunct Professor of Ophthalmology at Johns Hopkins University

- **Dr. Michel Michaelides:** Consultant Ophthalmologist at Moorfields Eye Hospital and Professor of Ophthalmology, UCL Institute of Ophthalmology

LBS-008
FOR DRY AMD & STARGARDT DISEASE

LBS 008

BRING

HOPE TO INCURABLE BLINDESS

For dry AMD & Stargardt Disease

- Discovery
- Preclinical
- Phase 1
- Phase 2
- Phase 3
- MARKET



KEY OPPORTUNITY

Zero Approved Treatments

FDA RPD ODD
for Stargardt (US & EU)

NIH **Blueprint**
Most Advanced Candidate

Dry AMD MARKET

11M

Blind victims suffer from macular degeneration in the US

$20B+

Estimated global market size

STGD MARKET

1 in 10,000

Stargardt Disease Juvenile onset macular degeneration (rare pediatric disease & orphan disease)

$1B+

Estimated global market size

Reference: Globaldata, Lancet, Orphanet, STEM CELLS Translational Medicine

LBS 008

Dry AMD number of patients: 9x to Wet AMD

Wet AMD:
- 10% of AMD Cases
- $6bn global sales in 2018



Dry AMD:
- 90% of AMD Cases
- 11mn patients in US alone
- 170mn patients globally

LBS 008

Pathogenesis of Stargardt & Dry AMD



Normal Retina | **RPE** Changes | **Rods** Die, **Cones** Spared | **Cones** Die



Vision Loss

LBS 008

Pathogenesis of Stargardt & Dry AMD

Case Study in the ProgStar study:

- The FAF from this STGD patient showed lipofuscin (A2E) is the direct driver for the lesion growth, and can predict the lesion growth location and rate.





The ProgStar Study Group, **Ophthalmology**, 2016; 123

LBS 008

RBP4 Transports Retinol (Precursor to Cytotoxic A2E) into Retina by Way of Visual Cycle

MOA: Stargardt & Dry AMD



LBS-008

Inhibits **RBP4** from delivering retinol into **RPE**, reducing **A2E** accumulation

RBP4

Primary transporter of retinol into **RPE**

IN ABCA4-/-RDH8-/- MICE, COMPARED TO LBS-008-TREATED

REDUCES A2E ACCUMULATION BY 80%



- Daily dosing of 25mg/kg of LBS-008 for 12 weeks.
- Significant 94.3% and 93.4% serum RBP4 reduction in LBS-008 treated mice at 1- and 12-week time points, respectively.
- ~80% A2E reduction in treated mice compared to DKO mice at 12-week timepoints.



IN ABCA4-/-RDH8-/- MICE, COMPARED TO LBS-008-TREATED

Photoreceptor Degeneration in Abca4-/-Rdh8-/- Mice

- Histological cross-section of retina near optic nerve, **Outer Nuclear Layer (ONL)** is the cell layer consisted of photoreceptor cell bodies (rods and cones).

Fawzi et al, Investigative ophthalmology & visual science 55(4) · March 2014



- **Dry AMD or STGD** is associated with thinning of **the ONL** and **the loss of photoreceptor cells,** indicating **macular degeneration.**
- ONL thickness was significantly decreased in the diseased group (abcd4/rdh8 knockout mice), as compared to the diseased group treated with LBS-008, ONL were preserved.



LBS 008

First and only dry AMD sponsored by NIH BluePrint Program
First drug to graduate and awarded 10mn funding from the NIH BluePrint Program

Reducing RBP4 is the recommended treatment for dry AMD & STGD by UK NIHR

HEALTH TECHNOLOGY ASSESSMENT
VOLUME 22 ISSUE 27 MAY 2018
ISSN 1366-5278

NHS
National Institute for Health Research

Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review

- 7,948 articles were screened for this Systematic Review on Treatments for dry AMD and Stargardt Disease. Principal findings include:
  - Research focus should be at earlier stages in both diseases, before vision is impaired.
  - Most promising treatments for dry AMD and STGD appear to be prevention of lipofuscin A2E accumulation.
  - Recommends Fenretinide as a promising treatment in dry AMD and STGD.
  - Acknowledges **LBS-008** works in a similar way to Fenretinide by reducing **RBP4** to prevent lipofuscin A2E accumulation.

LBS-007
FOR BROAD VARIETY OF CANCERS

Natural non-ATP CDC7 Inhibitor

for treatment of Broad Variety of Cancer types

LBS 007

- DISCOVERY
- PRE-CLINICAL
- PHASE I
- PHASE II/III
- MARKET



KEY OPPORTUNITY

Novel Anti-Cancer
Target Therapy

FDA ODD
for ALL (US)

MARKET

$5B
Expected 2026 market size of AML & ALL

1.7 in 100k
Acute lymphoblastic leukemia (orphan disease)

$55B
Expected 2023 market size of pancreatic, lung, ovarian cancers

$6B
Estimated global market

Reference: Globaldata, Marketwatch, NIH National Cancer Institute

Inhibits CDC7 in Cell Cycle Regulation







1 TARGETS
S Phase Progression

2 INHIBITS
CDC7's role in
DNA Replication

3 PREVENTS
Cell Division

LBS 007

Potently Inhibits Multiple Cancer Cell Lines & Primary Patient Samples of Blood Cancers



LBS-007 works well on small cell lung cancer and pancreatic cell lines

- LBS-007 achieved sub-μM (~150 nM) concentration efficacy against cancer cell lines
  - Small Cell Lung Cancer
  - Pancreatic Cancer

- LBS-007 performed better than
  - Cisplatin, a solid tumor drug with strong toxicity side effects
  - BMS-863233, an excellent CDC7 inhibitor from Bristol-Myers Squibb

Pancreatic Cancer



Small Cell Lung Cancer



Small Cell Lung Cancer



LBS-007 – Effective Against Blood Cancers



DOSE-RESPONSIVE MANNER

Inhibits **TKI-Resistant Acute Lymphoblastic Leukemia (ALL)** growth *in vivo* using a continuous infusion regimen

Reference: Unpublished data from Dr. Mark Frattini

LBS-007 – Also Effective Against Solid Tumors in Animal Models

Inhibits **Ovarian Tumor** growth *in vivo*



Reference: Unpublished data from Dr. Mark Frattini

All Indications are potential Blockbusters

Obtained RPD + ODD

LBS-008: Rare Pediatric Disease Designation (US) & Orphan Drug Designation (US & EU)
LBS-007: Orphan Drug Designation (US)

Eligible for PRV

Eligible for Priority Review Voucher upon NDA
Worth $150-350M upon transfer

Columbia technology + NIH Blueprint Sponsored

Most advanced candidate
$10M+ funding to date

Expected Drug Approval in 4 years

Seek Fast Track + Accelerated Approval based on RBP4 biomarker predicting clinical efficacy

$1B + 20B + 20B + 6B Market

Estimated global market for Stargardt + AMD + NASH + Leukemia / Multiple Solid Tumor

Targeted therapy for broad variety of cancer types

FDA ODD approved for ALL
Estimated global market $6B

Johnson & Johnson
Columbia University
NIH National Institutes of Health
NIH Blueprint Neurotherapeutics Network
NHS National Institute for Health Research

Thank You

This presentation is provided by Lin Bioscience, Inc. (“LBS”). The information contained within is not reviewed or reviewed by any accountant or any independent third party. Users should read this material in conjunction with all other public financial and operational information filed to the competent authorities by LBS. While we endeavor to provide accurate, complete and consistent information herein, LBS makes no guarantee or warranties as to the accuracy or correctness of all the material contained. After this presentation is released to the public, we undertake no obligation to update any relevant data to reflect any change hereafter.

Users should also notice that this presentation may contain forward-looking statements. Statements that are not historical facts, including statements relating to the implementation of strategic initiatives, future business development and economic performance are forward-looking statements. By their nature, forward-looking statements involve uncertainties, risks, assumptions and other factors that could cause actual developments and results to differ materially from our statement in this presentation. These factors include, but not limited to, regulatory developments, competitive conditions, technological developments, general economic conditions and management changes.

The information, statements or opinions in this presentation do not constitute a public offer under any applicable legislation or an offer to sell or solicitation of an offer to buy any securities or financial instruments or any advice or recommendation respect to such securities or other financial instruments. LBS and all its affiliates representatives, no matter for their negligence or any other reasons, should not be liable for any loss or damages arising from the use of or interpretation by others of information contained within this presentation or any matter related to this document.

Lin BioScience

Blindness & Cancer

Hao-Yuan Chuang, CFO
info@linbioscience.com